MedTrace Logo

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)

NCT01770613 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-04-27

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of human allogeneic mesenchymal bone marrow cells (aMBMC) administered intravenously to subjects with ST Segment Elevation Myocardial Infarction (STEMI).

Conditions

  • ST Segment Elevation Myocardial Infarction (STEMI)
  • Allogeneic Mesenchymal Bone Marrow Cells

Interventions

BIOLOGICAL

Stem cells

Allogeneic mesenchymal stem cells

Sponsors & Collaborators

  • CardioCell LLC

    collaborator INDUSTRY

  • Stemedica Cell Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Nabil Dib, MD, MSc, FACC · Mercy Gilbert Medical Center, Dignity Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2016-05-31
Completion
2017-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01770613 on ClinicalTrials.gov